Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -40.63
- Piotroski Score 4.00
- Grade Buy
- Symbol (ARDS)
- Company Aridis Pharmaceuticals, Inc.
- Price $0.00
- Changes Percentage (0%)
- Change -$0
- Day Low $0.00
- Day High $0.00
- Year High $0.09
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/21/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.16
- Trailing P/E Ratio -0.44
- Forward P/E Ratio -0.44
- P/E Growth -0.44
- Net Income $-30,749,000
Income Statement
Quarterly
Annual
Latest News of ARDS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Social media ban for UK under-16s 'not on the cards' for now, says minister
Minister Peter Kyle met with teenagers at NSPCC HQ who opposed a social media ban for under-16s, expressing concerns about reduced social connections. Kyle aims to enhance online safety through cooper...
By The Guardian | 20 hours ago -
Luke Bryan's Sneaky Steal and Other Things You Didn't See on TV at the 2024 CMA Awards
Luke Bryan, cohost of the CMA show, had a funny moment off-camera when he playfully tried to run off with a trophy before returning it. Other unseen moments included interactions between artists, fan ...
By PEOPLE.com | 1 day ago -
Kyle Richards Denies Sutton Stracke's Claims She Tried to 'Hook Up' with Kevin Costner: 'Definitely Not True'
RHOBH star Kyle Richards denied claims of trying to "hook up" with Kevin Costner in Aspen, labeling it a joke. Speculation about her relationship with Morgan Wade arose after separating from her husba...
By PEOPLE.com | 1 day ago
